Oridonin

Oridonin is an ent-kaurane tetracyclic diterpenoid first isolated from Isodon species, particularly Rabdosia rubescens. It has attracted significant research attention due to its diverse pharmacological properties, with anticancer effects being the most extensively studied. ## Pharmacological Properties Oridonin exhibits a wide range of biological activities: - **Anticancer effects**: Inhibits proliferation of various tumor cells, induces apoptosis, and shows anti-mutagenic effects. It can target multiple oncogenic proteins mainly via Michael addition between its unsaturated ketone and the proteins. - **Anti-inflammatory activity**: Helps ameliorate inflammation-related conditions. - **Anti-chemoresistance**: Effectively reverses cisplatin drug resistance in human ovarian cancer cells and shows anti-chemoresistance activity in cisplatin-resistant human gastric cancer cells. - **Other activities**: Shows potential in treating respiratory diseases, asthma, lupus-like symptoms, and possesses antibacterial properties. ## Chemical Properties - **Molecular formula**: C20H28O6 - **Molecular weight**: 364.4 g/mol - **Structure**: Organic heteropentacyclic compound and ent-kaurane diterpenoid - **Physical form**: White or off-white solid - **Melting point**: 248-250°C - **Solubility**: Soluble in DMSO (>20mg/mL) ## Mechanisms of Action Oridonin works through multiple mechanisms: - Regulates various gene and protein expressions (ALP, IL-6, TNF-α, Bcl-2, caspase-3, PGE2) - Affects signaling pathways including NF-κB, PI3K/Akt/mTOR, and ERK1/2 - Targets multiple oncogenic proteins including CRM1, PHGDH, HSP70, AML1-ETO, and STAT3 - Inhibits DNA, RNA, and protein synthesis in cancer cells. ## Clinical Development A water-soluble oridonin prodrug, HAO472, has advanced into Phase I clinical trials in China for treating acute myelogenous leukemia. Oridonin is also under investigation in clinical trial NCT05130892 (Effect of Inflammasome Inhibitor on Hscrp in Patients After PCI). ## Future Perspectives Despite its promising pharmacological activities, oridonin faces challenges: - The specific mechanism of its biological activity has not been fully explained at the molecular level - It has shown adverse effects and toxicity under specific circumstances - Further research is needed to balance toxicological safety and therapeutic efficacy. Researchers anticipate that new oridonin derivatives may emerge as anticancer drug candidates and enter additional clinical trials soon.